ミトラル弁の修復中の自発的な心臓内血栓形成の症例説明: アミノカプロ酸の合併症?
Nicolas A Zavala1,2, Tiffany G Liu1, Ashley Budd1
1From the Department of Anesthesiology, Northwestern Medicine, Feinberg School of Medicine, Chicago, Illinois.
A&A practice
|September 3, 2025
まとめ
心臓手術後の出血を予防するために使用されるエプシロン-アミノカプロ酸 (EACA) は,皮肉にも急性心臓内血栓症を引き起こす可能性があります. このケースは,心臓手術患者におけるEACAに関連した潜在的な血栓性リスクを強調しています.
科学分野:
- 心血管外科
- 血液学
- 薬理学について
背景:
- 心臓外科手術後の出血は重大な臨床的課題であり,患者の罹病率と死亡率を高めています.
- 心肺バイパスの後の凝固病は,炎症,血液希釈,低体温,および高線維解離を含む要因の複雑な相互作用によるものです.
- エプシロン-アミノカプロ酸 (EACA) のような抗繊維解剤は,特に血栓形成に関して,その安全性プロファイルは,継続的な調査を必要とします.
研究 の 目的:
- EACA投与直後に発生した急性心内血栓の報告
- EACAに関連する血栓性合併症の報告不足の可能性を強調する.
- 血栓性イベントに対する警戒が重要であることを強調する.
主な方法:
- ミトラル弁の修理を受けた患者の症例報告
- エプシロン- アミノカプロ酸 (EACA) の投与は,手術中の出血の管理のためである.
- EACA投与後の心臓内血栓の臨床観察と診断評価
主要な成果:
- EACAの投与直後に急性心臓内血栓が確認された.
- 患者には血液学的疾患や高血栓状態の既往歴はありませんでした.
- この事件は,心臓手術の文脈で,EACAと急性血栓の間の潜在的な因果関係を示唆しています.
結論:
- エプシロン- アミノカプロ酸 (EACA) は,出血を減少させるのに有効ですが,急性心内血栓症を含む認識されていない血栓性リスクと関連している可能性があります.
- EACAの投与スケジュールの変動は,血栓性合併症の発生率に影響を与える可能性があります.
- 心臓外科手術の患者におけるEACAの血栓形成の可能性を完全に解明するには,さらなる調査と報告が不可欠です.
関連する概念動画
01:26Aneurysm III: Interprofessional Care
24
Aneurysm management involves either conservative medical therapy or surgical intervention, depending on the size and symptoms of the aneurysm. Conservative management is generally reserved for smaller, asymptomatic aneurysms, while larger or symptomatic aneurysms often necessitate surgical repair.Conservative Medical TherapyFor small, asymptomatic aneurysms, particularly abdominal aortic aneurysms (AAA) less than 5.5 centimeters in diameter, conservative medical therapy is recommended. This...
24
01:22Mitral Stenosis I: Introduction
34
Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...
34
01:20Mitral Regurgitation I: Introduction
55
Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...
55
01:26Mitral Stenosis III: Medical Management
21
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
21
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
889
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
889